Weekly OXALF Chemotherapy for Elderly Patients with Advanced Gastric Cancer
Author Information
Author(s): D. Santini, G. Graziano, V. Catalano, M. Di Seri, E. Testa, A.M. Baldelli, P. Giordani, A. La Cesa, B. Spalletta, B. Vincenzi, A. Russo, M. Caraglia, V. Virzi, S. Cascinu, G. Tonini
Primary Institution: University Campus Bio-Medico, Rome, Italy
Hypothesis
The study aims to determine the response rate and toxicity of the OXALF regimen in elderly patients with advanced gastric cancer.
Conclusion
The OXALF regimen is an active and well-tolerated treatment for elderly patients with advanced gastric cancer.
Supporting Evidence
- The overall response rate was 45.2%, with two complete responses and 17 partial responses.
- The median survival time was 9.0 months.
- Toxicity was generally mild, with only three patients discontinuing treatment due to adverse events.
- The median time to disease progression was 5.0 months.
- Patients received a total of 540 treatment cycles, with a median of 12 cycles per patient.
Takeaway
This study tested a new chemotherapy treatment for older people with stomach cancer, and it worked well without causing too many side effects.
Methodology
Elderly patients aged 70 or older with advanced gastric cancer received weekly oxaliplatin, fluorouracil, and folinic acid.
Limitations
The study may not be generalizable to all elderly patients due to specific inclusion criteria.
Participant Demographics
Median age was 73 years, with 26 males and 16 females.
Statistical Information
Confidence Interval
95% CIs: 30%–56%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website